BioNTech Results Presentation Deck

On Track to Achieve Multiple Significant Data & Clinical Milestones in 2H 2021 Six Clinical Trial Initiations in 1H 2021, Including Two Randomized Phase 2 !!!! ✓BNT162b2: Multiple updates ● 5+ Trial Updates 33 BNT311: Bi-specific CPI: PD-L1 x 4-1BB in solid tumors BNT312: Bi-specific CPI: CD40 x 4-1 BB in solid tumors BNT211: CLDN-6 CAR-T + CARVac in solid tumors BNT411: TLR-7 agonist +/- CPI in solid tumors 3 Randomized Phase 2 Trial Starts BNT111: Fix Vac + CPI in CPI-R/R melanoma BNT113: FixVac HPV16+ + CPI in 1L HNSCC BNT122: iNeST (autogene cevumeran) in adjuvant m CRC TOPP ● 7 First-in-human Phase 1 Trial Starts BNT211: CLDN-6 CAR-T + CARVac in solid tumors BNT221: NEOSTIM individualized neoantigen-T cell therapy in melanoma BNT151: Ribocytokine (modified IL-2) BNT152+153: RiboCytokine IL-7 / IL-2 combo in solid tumors BNT141: RiboMab (undisclosed) BNT142: RiboMab bi-specific CPI in solid tumors (CD3xCLDN6) BNT161: Influenza vaccine program PD-L1, program med death-ligand 1; CLDN6, Claudin-6, CAR-T Cells, Chimeric Antigen Receptor T Cells; IL-2, Interleukin 2; IL-7, Interleukin 7; TLR-7, Toll-like receptor-7 CPI, Check-Point Inhibitor; HNSCC, Head and Neck Squamous Cell Carcinoma; mCRC, Metastatic Colorectal Cancer; iNeST is partnered with Genentech/Roche; BNT311 and BNT312 partnered with Genmab; BIONTECH

View entire presentation